

Table 9.6a
Immunosuppression Use for Induction, 2000 to 2009
Recipients with Liver Transplants

	Year of Transplant									
	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Transplants	5,001	5,195	5,332	5,673	6,171	6,444	6,651	6,494	6,319	6,320
With Immunosuppression Info	4,854	5,035	5,199	5,520	5,974	6,166	6,410	6,278	6,147	6,192
Induction Drugs										
ALG	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Atgam/NRATG/NRATS	0.7%	0.4%	0.5%	0.5%	0.4%	0.2%	0.3%	1.2%	1.1%	0.7%
OKT3	0.8%	0.7%	0.3%	0.3%	0.2%	0.8%	2.7%	2.9%	2.5%	2.4%
Thymoglobulin	1.2%	2.4%	4.2%	6.5%	7.4%	7.2%	9.0%	9.5%	10.3%	9.4%
Zenapax	6.6%	5.8%	4.6%	5.6%	4.8%	4.0%	5.8%	8.1%	7.8%	6.5%
Simulect	6.6%	6.2%	7.8%	7.2%	6.4%	7.1%	6.5%	5.6%	6.8%	8.7%
Campath	0.0%	0.0%	0.0%	0.7%	1.6%	1.6%	1.4%	1.4%	1.0%	0.7%
No Induction Drugs Recorded	84.5%	84.6%	82.7%	79.5%	79.4%	79.9%	77.2%	74.4%	73.4%	74.1%

Source: OPTN/SRTR Data as of October 1, 2010.

Notes:

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.

Individual induction drug percentages will not necessarily add up to 100 percent, as patients may be prescribed more than one induction drug.